Nurix Therapeutics (NRIX) investor relations material

Executive summary

• Q3 revenue was $673.1M and net income was $549.8M, driven by $653.2M of Roche license revenue.

• Cash, cash equivalents and marketable securities totaled $1.1B at Aug. 31, with stated runway into H2 2029.

• Bexobrutideg entered Phase 3; NX-1607 advanced into Phase 1b expansion cohorts, while NX-2127 development was discontinued.

Financial highlights

• Q3 revenue was $673.1M vs. $7.9M YoY, including $653.2M of Roche license revenue and a $10.0M Sanofi milestone; nine-month revenue was $688.4M vs. $70.4M.

• Q3 net income was $549.8M vs. an $86.4M loss; nine-month net income was $373.1M vs. an $186.2M loss.

• Q3 operating expenses were $113.6M vs. $99.3M YoY; R&D was $79.3M vs. $86.1M and G&A was $34.4M vs. $13.2M.

• Q3 collaboration revenue was $19.9M vs. $7.9M; nine-month collaboration revenue was $35.2M vs. $40.4M.

Outlook and guidance

• Cash, cash equivalents and marketable securities of $1.1B following the $700M Roche upfront support stated runway into H2 2029.

• R&D and G&A expenses are expected to rise as clinical programs advance, manufacturing scales, commercial readiness develops and infrastructure expands.

• Significant additional funding will be needed for long-term plans; potential sources include equity, debt, collaborations, strategic alliances and licensing arrangements.